New US bill introduced to tackle pay-for-delay settlements between drug makers
This article was originally published in SRA
A US congressman has introduced yet another bill to block the so-called pay-for-delay deals between research-based and generic drug makers1,2.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.